Clinical Trials Directory

A Study of Bortezomib With Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia

This is a Phase I/II study of a drug called bortezomib given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). Bortezomib is a drug that has been approved by the Food and Drug Administration (FDA) for treating adults with multiple myeloma which is a type of blood cancer. Bortezomib has been shown to cause cancer cells to die in studies done on animals (mice). Studies have been done that have shown that some adults and children with cancer have shown a response to bortezomib when it is used alone. Studies have also been done in adults to evaluate the dose of bortezomib that can be safely given in combination with other chemotherapy drugs. The Phase I portion of this study is complete and the dose for the phase II portion of the study is 1.3mg/m2/day. The phase II portion of the study is open and accruing.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Intervention(s):

  • drug : bortezomib (Velcade)
  • drug : dexamethasone
  • drug : PEG-asparaginase
  • drug : vincristine
  • drug : cytarabine
  • drug : methotrexate
  • drug : doxorubicin

Phase: Phase 1/Phase 2

Eligibility

Ages Eligible For Study:

1 Year - 21 Years

Inclusion Criteria

- Patients must be greater than 1 year and less than 21 years of age to participate in this study. - Patients must have relapsed acute lymphoblastic leukemia (ALL) with or without evidence of central nervous system (CNS) disease. - Patients must have adequate kidney, heart, and liver function.

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs
650-723-5535
Not Recruiting

Footer Links: